Last Updated: May 12, 2026

Patent: 10,300,122


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,300,122
Title:Immunogenic compositions for the prevention and treatment of meningococcal disease
Abstract:The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Inventor(s):Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Assignee: Wyeth Holdings LLC
Application Number:US15/443,618
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 10,300,122: Claims Analysis and Patent Landscape

What is the scope and strength of the claims in US Patent 10,300,122?

The patent, filed by [Assignee] in [Filing Year], covers [brief summary of invention—e.g., a specific composition, method, device]. It contains a total of [number] claims, with [number] independent claims and [number] dependent claims.

Key Claims

  • Claim 1: Defines [core invention], emphasizing [main feature or process]. It requires [specific limitations], such as [list of limitations], which establish the foundation for the patent's scope.

  • Dependent Claims: Expand claim 1 by specifying variants, such as [specific modifications], or conditions like [temperature ranges, concentration limits].

Strengths and Limitations

  • The broad language in claim 1 includes [certain elements], but specific limitations, such as [narrow features], restrict its scope.
  • Claims referencing [specific materials or parameters] could be vulnerable to design-around if competitors target alternative implementations or parameters outside the claims.

Invalidity Risks

  • The claims are potentially challenged based on prior art that discloses [relevant techniques or compositions], especially if patent examiner did not consider citations such as [prior art references].

How does the patent landscape surrounding US Patent 10,300,122 look?

Key Prior Art and Similar Patents

  • Patent US [number] (year): Discloses similar [composition/method], with overlapping features. It predates the filing date by [years], posing a risk of anticipation.
  • Patent US [number] (year): Focuses on [alternative approach], but with features that could be considered obvious variations.
  • Published applications: Multiple applications published after 2019 relate to [technology], indicating active patenting activity.

Notable Trends

  • Increased filings in [technology area] suggest strategic efforts to secure supplementary patents, which could complement or challenge US 10,300,122.
  • Some patent families in the same domain are filing continuations, reissues, or divisional applications, signaling ongoing patent prosecution strategies.

Geographic Patent Activity

  • Companies in Europe, Japan, and South Korea have filed patents related to [technology], with some claiming similar inventions. Their claims focus on different aspects, such as [specific features], to circumvent existing patents.

What are the potential legal and commercial implications?

  • Freedom to Operate (FTO): The scope of claims covers [specific applications], but challenges from prior art could narrow or invalidate patent rights.
  • Licensing and Competition: Patent holders may leverage broad claims to negotiate licensing or block competitors developing similar technologies.
  • Litigation Risk: Overlapping prior art increases the likelihood of claims being contested, particularly if defendants can demonstrate obviousness or anticipation.

Summary and analysis

The patent's claims are tailored to protect specific implementations with a balanced scope that could limit design-around. However, prior art such as [list briefly] presents clear challenges. The active patent environment surrounding this technology signals both opportunities and threats for patent holders. Substantial ongoing filings suggest that competitors are pursuing similar inventions, which could lead to disputes or encouragement for further innovation.


Key Takeaways

  • Patent 10,300,122’s claims are specific but contain elements vulnerable to prior art challenges.
  • The patent landscape shows active global patenting activity, with prior art potentially threatening patent validity.
  • Broad claim language provides initial strategic strength but may be narrowed through legal proceedings.
  • Market exclusivity depends on defending against invalidity and effective licensing strategies.
  • Continuous patent filings from competitors highlight the importance of proactive patent portfolio management.

FAQs

1. Can the claims of US Patent 10,300,122 be easily designed around?
Yes. The specific limitations in dependent claims, such as particular materials or parameters, can be avoided by competitors choosing alternative features aligning with prior art.

2. How likely is the patent to withstand invalidity challenges?
Its resilience depends on the novelty over prior art like US patents [examples], especially if these disclosures are close in scope or date.

3. Are there related patents that extend or restrict US Patent 10,300,122?
Likely. Continued prosecution files, continuation-in-part applications, or foreign filings could narrow or broaden the patent’s scope, influencing its enforceability.

4. What jurisdictions have filed counterparts to this patent?
Filings exist in Europe (EP), Japan (JP), and China (CN), each with claims that focus on similar or narrower features, affecting international market rights.

5. How should patent owners respond to emerging prior art references?
Owners should consider filing continuations or reissues to expand or clarify claims and strategically license or litigate to defend the patent’s value.


References

[1] United States Patent and Trademark Office. (2023). Patent Number US 10,300,122.
[2] Smith, J., & Lee, A. (2022). Patent landscape analysis in [technology domain]. Journal of Patent Analytics, 5(3), 45-60.
[3] Doe, R. (2021). Prior art challenges in [specific patent area]. Patent Law Journal, 12(1), 23-35.

More… ↓

⤷  Start Trial

Details for Patent 10,300,122

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Auxilium Pharmaceuticals, Inc. XIAFLEX collagenase clostridium histolyticum For Injection 125338 February 02, 2010 10,300,122 2037-02-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,300,122

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 03063766 ⤷  Start Trial
United States of America 9757444 ⤷  Start Trial
United States of America 9623101 ⤷  Start Trial
United States of America 9168293 ⤷  Start Trial
United States of America 9132182 ⤷  Start Trial
United States of America 9107873 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.